Maya Martinez-Davis

Maya Martinez-Davis joined GSK in September 2019 to lead the $20B+ pharmaceuticals and vaccines businesses in the US and Puerto Rico as President, US Pharmaceuticals, effective January 1, 2020.

Previously she served as president of the Biopharma Latin America business for Merck KGaA, Darmstadt, Germany. Maya used her proven expertise driving pharmaceutical business in developed and emerging markets to her role at Merck KGaA, in which she oversaw 14 countries and over 1,000 employees. She guided the region’s strategy for continued business growth by both delivering the company’s planned medical launches and further developing its core healthcare business. Maya led the Regional Leadership Team, where she worked closely with General Managers and heads of regional functions, while also serving as a member of the International Operations Leadership Team.

Maya joined Merck KGaA, Darmstadt, Germany in 2016 as Senior Vice President and Head of Global Oncology for the biopharma business. Aside from leading avelumab (BAVENCIO®) worldwide launch, she supported Merck’s transformation into a recognized global oncology innovator. She also played a critical role in establishing collaborations to strengthen Merck’s presence in the oncology field, including making significant contributions to the alliance with Pfizer. Prior to joining Merck KGaA, Darmstadt, Germany Maya worked at Pfizer as a senior executive for over a decade, where she exercised her vast cross-border, regional and global leadership experience to boost sales growth and market penetration in the areas of Oncology, vaccines and specialty portfolios. In her last role, Maya oversaw the company’s oncology business in the US, managing a large-scale cross-functional team and leading product introductions and launches across multiple tumor types.

Maya holds an undergraduate degree from Saint Louis University and a master’s in business leadership and marketing from the IE Business Institute in Madrid, Spain.